Open Government Portal
MaintenanceWe are performing scheduled maintenance from 8:00am to 12:00pm, Monday, December 4th, Eastern time.
The Canadian Nuclear Safety Commission (CNSC) is publishing total annual releases of radionuclides released directly to the environment from nuclear facilities.
This update includes 2022 radionuclide loading data. Please refer to the Notes and Changes spreadsheet for a list of changes.
The Food Source Contribution Table (FSCT) provides estimates of how much various food groups and subgroups contribute to Canadians’ intakes of energy and selected nutrients using data collected in the 2015 Canadian Community Health Survey (CCHS) - Nutrition.
Two different datasets are available. The first file provides data for recipes as a whole along with food consumed on its own. The second file provides data for recipes broken down into their ingredients along with food consumed on its own.
The User Guide and Food Group Lists provide detailed information to facilitate use of the FSCT.
All institutions subject to the Access to Information Act are required to post summaries of completed access to information (ATI) requests within thirty calendar days after the end of each month.
Download a dataset of Completed Access to Information Request Summaries from federal institutions below.
Requests focusing on personal information or third-party proprietary information are not included in these datasets. Not all federal institutions post their Completed Access to Information Request Summaries on the Open Government Portal and such information is not captured in the datasets.
In addition to the downloadable dataset, a link is available below as a resource …
This guidance document addresses the development of contraceptive products, intended for use by women during their reproductive years, which contain sex steroids as active ingredient(s).
These guidelines have been developed by a Therapeutic Products Programme's Working Group for the Toxicological Assessment of Contraceptive Steroids in close consultation with several experts in the fields of toxicology, pathology and reproductive physiology.
This guidance has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. The ICH Steering Committee has endorsed the final draft and recommended its adoption by the regulatory bodies of the European Union, Japan and USA.
This guidance is intended to harmonize and to update the prescribing information for nonsteroidal anti-inflammatory drugs () indicated for controlling pain and inflammation associated with rheumatic diseases and other less severe conditions.
Canada's regulatory approach: Drugs for rare diseases are authorized for sale in Canada under the Food and Drugs Act and Part C of the Food and Drug Regulations.
Health Canada’s Therapeutic Products Directorate (TPD) and Biologics and Genetic Therapies Directorate (BGTD) are responsible for reviewing the applications for authorization to sell or import drugs for the purposes of conducting clinical trials in Canada.
Health Canada has authorized certain clinical trials in patients in Canada. Our public Clinical Trials Database is a public listing of specific information relating to these trials. Additional publicly accessible registries that further support finding suitable trials are: ClinicalTrials.gov and Current Controlled Trials International Standard Randomized Controlled Trials Number Register.